![Charles Osborne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charles Osborne
Direttore Finanziario/CFO presso POLAREAN IMAGING PLC
Posizioni attive di Charles Osborne
Società | Posizione | Inizio | Fine |
---|---|---|---|
POLAREAN IMAGING PLC | Direttore/Membro del Consiglio | 22/02/2021 | - |
Direttore Finanziario/CFO | 29/04/2019 | - |
Storia della carriera di Charles Osborne
Precedenti posizioni note di Charles Osborne
Società | Posizione | Inizio | Fine |
---|---|---|---|
Innocrin Pharmaceuticals, Inc.
![]() Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Direttore Finanziario/CFO | 05/07/2015 | 01/04/2019 |
Segretario Aziendale | 01/07/2015 | 01/04/2019 | |
SCYNEXIS, INC. | Direttore Finanziario/CFO | 01/11/2003 | 30/06/2015 |
International Murex Technologies Corp.
![]() International Murex Technologies Corp. Medical SpecialtiesHealth Technology International Murex Technologies Corp. develops medical diagnostic products. It provides infectious disease screening services. The company is headquartered in Norcross, GA. | Direttore Finanziario/CFO | - | - |
Nobex Corp.
![]() Nobex Corp. Pharmaceuticals: MajorHealth Technology Protein Delivery Inc. is drug delivery company. It specializes in proprietary polymer-based technology for the stabilization and oral delivery of proteins and peptides as well as the delivery of small molecules across the blood-brain barrier. The company's technology also enables the delivery of drugs into the brain to treat diseases of the central nervous system. Protein Delivery is located in Durham, NC | Direttore Finanziario/CFO | - | - |
Formazione di Charles Osborne
The University of North Carolina at Charlotte | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Regno Unito | 2 |
Posizioni
Director of Finance/CFO | 5 |
Undergraduate Degree | 1 |
Corporate Secretary | 1 |
Settori
Health Technology | 6 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
SCYNEXIS, INC. | Health Technology |
POLAREAN IMAGING PLC | Health Technology |
Aziende private | 3 |
---|---|
Nobex Corp.
![]() Nobex Corp. Pharmaceuticals: MajorHealth Technology Protein Delivery Inc. is drug delivery company. It specializes in proprietary polymer-based technology for the stabilization and oral delivery of proteins and peptides as well as the delivery of small molecules across the blood-brain barrier. The company's technology also enables the delivery of drugs into the brain to treat diseases of the central nervous system. Protein Delivery is located in Durham, NC | Health Technology |
International Murex Technologies Corp.
![]() International Murex Technologies Corp. Medical SpecialtiesHealth Technology International Murex Technologies Corp. develops medical diagnostic products. It provides infectious disease screening services. The company is headquartered in Norcross, GA. | Health Technology |
Innocrin Pharmaceuticals, Inc.
![]() Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Charles Osborne
- Esperienza